+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effects of licochalcon A on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats



Effects of licochalcon A on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats



Die Pharmazie 68(11): 882-888



Losartan and licochalcon A interact with cytochrome P-450 (CYP) enzymes and P-glycoprotein (P-gp), and the increase in the use of health supplements may result in licochalcon A being taken concomitantly with losartan to treat or prevent cardiovascular diseases as a combination therapy. The effect of licochalcon A, a natural flavonoid, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, was investigated in rats. Pharmacokinetic parameters of losartan and EXP-3174 were determined after oral administration of losartan (9 mg/kg) to rats in the presence or absence of licochalcon A (0.5, 2.5 and 10 mg/kg). The effect of licochalcon A on P-glycoprotein (P-gp) as well as CYP3A4 and 2C9 activities was also evaluated. Licochalcon A inhibited CYP3A4 and CYP2C9 enzyme activities with 50% inhibition concentrations (IC50) of 2.0 and 0.1 microM, respectively. In addition, licochalcon A significantly enhanced the cellular accumulation of rhodamine-123 in a concentration-dependent manner in MCF-7/ADR cells overexpressing P-gp. The pharmacokinetic parameters of losartan were significantly altered by licochalcon A. Licochalcon A (2.5 mg/kg or 10 mg/kg) increased AUC0-infinity of losartan by 33.4-63.2% and Cmax of losartan by 34.0-62.8%. The total body clearance (CL/F) was significantly decreased (2.5 mg/kg, p < 0.05; 10 mg/kg, p < 0.01) by licochalcon A. Consequently, the absolute bioavailability of losartan in the presence of licochalcon A increased significantly (2.5 mg/kg, p < 0.05; 10 mg/kg, p < 0.01) compared to that in the control group. The relative bioavailability (R.B.) of losartan was 1.15- to 1.63-fold greater than that of the control group. However, there was no significant change in Tmax and t1/2 of losartan in the presence of licochalcon A. Licochalcon A (10 mg/kg) increased the AUC0-infinity of EXP-3174 but this was not significant. Furthermore, concurrent use of licochalcon A (10 mg/kg) significantly decreased the metabolite-parent AUC ratio (M.R.) by 20%, suggesting that licochalcon A inhibited the CYP-mediated metabolism of losartan to its active metabolite, EXP-3174. In conclusion, the enhanced oral bioavailability of losartan in the presence of licochalcon A may mainly result from decreased P-gp-mediated efflux transporter in the small intestine and from the inhibition of CYP 3A- and CYP2C9-mediated metabolism in the small intestine and liver and/or from the reduction of total body clearance of losartan by licochalcon A.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 052873569

Download citation: RISBibTeXText

PMID: 24380237


Related references

Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174. International Journal of Clinical Pharmacology and Therapeutics 50(9): 683-689, 2013

Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers. European Journal of Clinical Pharmacology 65(6): 585-591, 2009

Pharmacokinetics of losartan and its active carboxylic acid metabolite E-3174 in five ethnic populations of China. Journal of Clinical Pharmacy and Therapeutics 37(2): 226-231, 2012

Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin. Journal of Pharmacy and Pharmacology 62(7): 908-914, 2011

The kinetics of losartan and its active metabolite EXP 3174 in rats Intestinal vs hepatic processes. Pharmazie 53(3 SUPPL 1): 13, 1998

Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. Pharmacology 88(1-2): 1-9, 2012

HPLC assays to stimultaneously determine the angiotensin-AT1 antagonist losartan as well as its main and active metabolite EXP 3174 in biological material of humans and rats. Journal of Pharmaceutical & Biomedical Analysis 16(5): 863-873, 1998

Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clinical Pharmacology and Therapeutics 71(1): 89-98, 2002

Acute effects of E-3174, a human active metabolite of losartan, on the cardiovascular system in tachycardia-induced canine heart failure. Hypertension Research 24(1): 65-74, 2001

Acute Effects of E-3174, a Human Active Metabolite of Losartan, on the Cardiovascular System in Tachycardia-Induced Canine Heart Failure. Hypertension Research 24(1): 65-74, 2001

Candesartan, an Insurmountable Antagonist of Angiotensin II-mediated Contractile Effects in Isolated Vascular Preparations: Comparison with Irbesartan, Losartan and its Active Metabolite (EXP-3174). Blood Pressure 9(Sup1): 50-51, 2000

A convenient synthesis by microwave irradiation of an active metabolite (EXP-3174) of losartan. Tetrahedron Letters 44(6): 1149-1152, 2003

Candesartan Causes Long-lasting Antagonism of the Angiotensin II Receptor-mediated Contractile Effects in Isolated Vascular Preparations: a Comparison with Irbesartan, Losartan and its Active Metabolite (EXP-3174). Blood Pressure 9(Sup1): 52, 2000

Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174. Clinical Pharmacology and Therapeutics 59(3): 268-274, 1996

The metabolism of losartan to the active metabolite E-3174 in subjects who are extensive and poor metabolizers of debrisoquine or mephenytoin. British Journal of Clinical Pharmacology 43(2): 215, 1997